PD-L1 DAKO Test: Comprehensive Immunohistochemistry Analysis for Cancer Treatment
Understanding the PD-L1 DAKO Test
The PD-L1 DAKO test represents a groundbreaking advancement in precision oncology, utilizing sophisticated immunohistochemistry (IHC) technology to detect programmed death-ligand 1 protein expression in cancer cells. This revolutionary diagnostic approach has transformed cancer treatment by identifying patients who are most likely to benefit from immunotherapy, particularly immune checkpoint inhibitors that have shown remarkable success in treating various malignancies.
What Does the PD-L1 DAKO Test Measure?
The PD-L1 DAKO test specifically measures the presence and density of PD-L1 proteins on the surface of tumor cells and immune cells within the tumor microenvironment. This critical biomarker assessment helps determine:
- PD-L1 protein expression levels in tumor tissue
- Tumor proportion score (TPS) indicating percentage of PD-L1 positive tumor cells
- Combined positive score (CPS) evaluating both tumor and immune cell expression
- Immune cell infiltration patterns within the tumor microenvironment
Who Should Consider PD-L1 DAKO Testing?
This advanced diagnostic test is particularly valuable for patients with:
- Confirmed diagnoses of non-small cell lung cancer (NSCLC)
- Advanced or metastatic solid tumors
- Patients being considered for immunotherapy treatment
- Individuals with recurrent or treatment-resistant cancers
- Those seeking personalized cancer treatment options
Clinical Indications and Symptoms
Patients experiencing persistent symptoms or diagnosed with cancers that commonly respond to immunotherapy should discuss PD-L1 testing with their oncologist. These include individuals with unexplained weight loss, persistent cough, abnormal bleeding, or other cancer-related symptoms that haven’t responded to conventional treatments.
Benefits of PD-L1 DAKO Testing
Undergoing PD-L1 DAKO testing provides numerous clinical advantages:
- Personalized Treatment Planning: Identifies patients most likely to respond to immunotherapy
- Improved Treatment Outcomes: Helps avoid ineffective treatments and associated side effects
- Cost-Effective Care: Directs resources toward therapies with higher success probabilities
- Enhanced Quality of Life: Reduces exposure to treatments that may not provide benefit
- Informed Decision Making: Provides crucial data for treatment discussions with healthcare providers
Understanding Your Test Results
PD-L1 DAKO test results are typically reported as numerical scores or percentages that indicate the level of PD-L1 expression:
- High Expression: Typically indicates better response to immunotherapy
- Low Expression: May suggest alternative treatment approaches
- Negative Results: Could indicate limited benefit from specific immunotherapies
Your oncologist will interpret these results in the context of your specific cancer type, stage, and overall health to develop the most appropriate treatment plan.
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| Discount Price | $500 |
| Regular Price | $876 |
Test Specifications
- Turnaround Time: 7-8 days
- Sample Type: Tissue Blocks
- Methodology: Immunohistochemistry (IHC)
- Required Materials: Properly packed and previously labelled slides and blocks with clinical details and proper requisition form
Convenient Testing Locations Across USA
We have branches in all major cities throughout the United States, making PD-L1 DAKO testing accessible and convenient. Our state-of-the-art facilities in New York, Los Angeles, Chicago, Houston, and other metropolitan areas ensure you receive the highest quality diagnostic services with rapid turnaround times.
Pre-Test Instructions
The PD-L1 DAKO test requires a doctor’s prescription for most cases. However, prescription requirements do not apply to surgery and pregnancy cases or individuals planning international travel. Please consult with your healthcare provider to determine if this test is appropriate for your specific situation.
Take Control of Your Cancer Treatment Journey
Don’t leave your treatment decisions to chance. The PD-L1 DAKO test provides critical information that can significantly impact your cancer treatment outcomes. By understanding your tumor’s molecular characteristics, you and your healthcare team can make more informed decisions about the most effective treatment strategies.
Ready to schedule your PD-L1 DAKO test? Call or WhatsApp us today at +1(267) 388-9828 to book your appointment and take the first step toward personalized cancer care.
